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Purpose: To evaluate the influence of rapamycin on endothelial-mesenchymal transition and matrix metalloproteinase
(MMP) secretion by human umbilical vein endothelial cell line EA.hy926 and explore rapamycin’s angiogenesis inhibition
mechanism.
Methods: EA.hy926 cells were cultivated in vitro. After the cells attained complete confluency, an artificial scratch was
made through the monolayer with a sterile plastic 100 μl micropipette tip. Cell morphology changes were observed. The
expression of vascular endothelial (VE)-cadherin, vimentin, and Twist protein were examined by immunofluorescence.
After scratching, the cells were treated with 10, 100, and 1,000 ng/ml rapamycin for durations of 24, 48, and 72 h. Cell
proliferation was then assessed using methyl thiazolyl tetrazolium assay. Cell migration ability was examined, and the
expression of VE-cadherin, vimentin, and the Twist transcription factor in mRNA levels was evaluated with reverse
transcriptase PCR. The expression of gelatinases (MMP-2 and MMP-9) was examined using gelatin zymography.
Results: After scratching, the endothelial cells were able to migrate via an endothelial-to-mesenchymal transition, which
was related to Twist expression. Finally, mesenchymal cells transitioned into endothelial cells and reached cell confluency
again. The growth of EA.hy926 cells was not affected by rapamycin concentrations of 10 ng/ml or 100 ng/ml during
treatment periods of 1, 2, and 3 days; however, cell growth was inhibited by 1,000 ng/ml rapamycin with a three-day
treatment period. Rapamycin successfully inhibited cell migration at concentrations of 10 ng/ml, 100 ng/ml, and 1,000
ng/ml for a treatment period of up to 8 h. Different concentrations of rapamycin induced the expression of VE-cadherin,
inhibited vimentin and Twist expression in the endothelial cells, and inhibited endothelial cell secretion of MMP-2 and
MMP-9.
Conclusions: Rapamycin inhibited cell migration and extracellular matrix degradation by inhibiting endothelial-to-
mesenchymal transition and the endothelial cell secretion of MMP-2 and MMP-9; these may be possible mechanisms for
the inhibition of angiogenesis by rapamycin.
Neovascularization is a complex process and is tightly
regulated  by  many  positive  and  negative  factors  [1-5].
Endothelial  cell  migration  plays  an  important  role  in
angiogenesis  [6].  Rapamycin  is  an  immunosuppressive
macrolide. Its strong immune inhibition effects, as well as its
ability to effectively inhibit corneal neovascularization and
tumor  angiogenesis  [4,7],  have  gained  much  attention.
Rapamycin  has  effectively  inhibited  angiogenesis  by
inhibiting  endothelial  cell  migration  and  proliferation  [4].
However, very little is known about the mechanism by which
rapamycin  inhibits  endothelial  cell  migration.  This  might
occur  by  the  direct  suppression  of  mammalian  target  of
rapamycin (mTOR) expression [4] and reduction of vascular
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endothelial growth factor (VEGF) expression [8] or through
some  other  mechanism.  The  endothelial-to-mesenchymal
transition  (EndoMT),  whereby  endothelial  cells  can
transdifferentiate  into  mesenchymal  cells  accompanied  by
decreased  endothelial  markers  (vascular  endothelial  [VE]-
cadherin) and increased mesenchymal markers (vimentin), is
an  important  step  of  angiogenesis  during  embryo
development [9,10], as well as in kidney fibrosis and other
fibrotic diseases [11,12]. It is still not clear whether rapamycin
inhibits  endothelial  cell  migration  by  inhibiting  EndoMT.
Kwon found that rapamycin had not affected the expression
of MMP-9 mRNA (mRNA) in the alkaline-burned cornea
[4], but many reports have also found that rapamycin may
suppress the expression of MMPs [13-15]. Therefore, this
study focused on whether EndoMT occurred during the cell
migration  process,  and  whether  rapamycin  inhibited
endothelial cell migration by inhibiting EndoMT and blocking
the production of MMP-2 and MMP-9.
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Materials: An EA.hy926 cell line was generously provided
by Cora-Jean S. Edgell from the University of North Carolina
at Chapel Hill and the Tissue Culture Facility in the United
States.  Additional  materials  included  fetal  bovine  serum
(FBS; Gibco Company); goat polyclonal antibodies specific
for human Twist (Santa Cruz Company, Santa Cruz, CA); and
mouse monoclonal antibodies (Mabs) binding to the human
cell  type–specific  protein  VE-cadherin  (Santa  Cruz
Company). Rabbit polyclonal antibodies specific for human
vimentin,  fluorescein  isothiocyanate  (FITC)-labeled  goat
antirabbit IgG antibody, FITC-labeled rabbit antigoat IgG
antibody and tetramethyl rhodamine isothiocyanate (TRITC)-
labeled goat antimouse IgG antibody were from Zhongshan
Golden  Bridge  Biotechnology  Co.  Ltd.  (Beijing,  China).
Primers  were  purchased  from  the  Invitrogen  Corporation
(China).  Rapamycin  was  provided  by  the  North  China
Pharmaceutical Group New Drug Research and Development
Center. All chemical reagents were of analytical grade and
were purchased from Sigma.
Cell  cultures:  The  EA.hy926  cell  line,  a  permanent
endothelial  cell  line  derived  from  human  umbilical  vein
endothelial  cells  (HUVECs)  by  fusion  with  the  lung
carcinoma cell line A549, were maintained in Dulbecco’s
Modified  Eagle’s  Medium  (DMEM)-high  glucose  with
4500 mg/l glucose (Gibco, Carlsbad, CA), supplemented with
10%  FBS  at  37  °C  in  a  5%  CO2  incubator.  When  the
experiment was conducted, EA.hy926 cells were seeded in
tissue culture plates and maintained in DMEM-high glucose
with 4500 mg/l glucose, supplemented with 2% FBS. A 5 mg/
ml  rapamycin  stock  solution  was  prepared  in  dimethyl
sulfoxide  (DMSO;  Xinxing  Chemicals  Company,  Panjin,
China) and stored at −20 °C. The culture medium was replaced
with rapamycin-containing medium (10, 100, and 1,000 ng/
ml rapamycin) or vehicle control medium (0.1% DMSO in
fresh medium).
Endothelial  cell  morphology  and  immunofluorescence
staining: EA.hy926 cells were seeded in 96-well tissue culture
plates  in  amounts  of  5×103  cells/well.  After  complete
confluency, an artificial scratch approximately 300 μm wide
was made through the monolayer with a sterile plastic 100 μl
micropipette tip. After 24 h, 48 h, and 72 h of incubation, cell
morphology  changes  were  observed  under  inverted
microscope. The expression of VE-cadherin, vimentin, and
Twist  protein  was  examined  using  immunofluorescence
staining.  Primary  antibodies  were  VE-cadherin  mouse
antihuman,  vimentin  rabbit  antihuman,  and  Twist  goat
antihuman;  secondary  antibodies  were  FITC-labeled  goat
antirabbit IgG, TRITC-labeled goat antimouse IgG antibody,
FITC-labeled rabbit antigoat IgG, and nucleus stained with
Hoechst  (Beyotime  Institute  of  Biotechnology,  Shanghai,
China). Finally, the cells were visualized and photographed
with an Olympus fluorescence microscope (Olympus BX60,
Tokyo, Japan).
Cell proliferation analysis: The cells (5×103) were inoculated
in 96-well plates (150 µl/well), incubated for 12 h, and serum-
starved overnight. Cell proliferation was measured using 3-
(4,  5)-dimethylthiahiazo  (-z-y1)-3,  5-di-
phenytetrazoliumromide  (MTT)  [16].The  cells  were
separately treated with 10, 100, and 1000 ng/ml rapamycin for
durations of 24, 48, and 72 h, with six wells for each group.
The cells of the control group were left untreated. 3-(4,5)-
dimethylthiahiazo  (-z-y1)-3,  5-di-  phenytetrazoliumromide
(MTT, Sigma; 5 g/l) was used as an incubation solution, and
the wells were incubated for 4 h. DMSO (150 µl) was added
to the culture medium with low-speed oscillation for 10 min.
The optical density (A value) was measured at 492 nm with a
continuous  spectrum  densitometer  (Spectra  Max  M2;
Molecular Devices, Sunnyvale, CA).
Cell migration ability examination: The cells (5×103) were
inoculated in 96-well plates (150 µl/well). An artificial scratch
was  performed  after  complete  confluency  and  separately
treated with 10, 100, or 1000 ng/ml rapamycin for a duration
of 8 h. The cells of the control group were left untreated.
Photographs of treated cells within the scratch were taken with
a phase-contrast microscope (magnification of 100×; Nikon
Diaphot 300; Nikon, Tokyo, Japan) connected to a digital
camera. We randomly selected six photographs and counted
the cells that had moved into the wounded area in the selected
photographs.
Evaluation of the gene expression of vascular endothelial-
cadherin,  vimentin,  and  Twist:  The  cells  (500×103)  were
inoculated  in  6-well  plates  (2  ml/well).  After  reaching
confluency, the cells were randomly divided into three groups:
(1) the no-scratch group, (2) the scratch group, and (3) the
rapamycin group was further divided into three groups: after
being artificially scratched, the cells were separately treated
with 10, 100, and 1,000 ng/ml of rapamycin for an incubation
of 24 h. The cells were collected by centrifugation and the
total RNA was extracted with the NucleoSpin RNA II System
(Company Macherey-Nagel, Düren, Germany) according to
the manufacturer’s protocol. PCR primers were designed on
the basis of the published human gene sequences (Table 1).
Reverse transcriptase–PCR was performed to evaluate the
expression  of  these  genes  in  EA.hy926  cells  using  the
housekeeping  gene  glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) as an internal control [17].
Gelatin zymography: The endothelial cells of each group were
incubated  according  to  the  protocol  used  for  reverse
transcriptase–PCR. The culture supernatants were harvested
at 24 h and mixed with a gel sample buffer (0.5M Tris-HCl,
glycerol,  10%  sodium  dodecyl  sulfate  [SDS],  β-
mercaptoethanol,  and  0.5%  bromophenol  blue).  Ten
micrograms of protein were taken by SDS PAGE (PAGE)
separation;  the  SDS–PAGE  gels  contained  0.1%  gelatin
(Sigma) [18]. After electrophoresis, the gels were washed in
50 mM Tris buffer containing 2.5% Triton X-100. The gels
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(50 mM Tris buffer [pH 7.6], 10 mM CaCl2, and 200 mmol/l
NaCl). The gels were stained with 0.5% Coomassie blue that
contained 30% methanol and 10% glacial acetic acid and
subsequently destained in 45% methanol/10% acetic acid/
H2O. White bands on a blue background indicated zones of
digestion corresponding to the presence of different MMPs.
Gels were scanned, and a density analysis of the bands was
performed using ImageJ software.
Statistical analysis: All values in the figures and text were
expressed  as  mean±standard  deviation  (SD)  of  three
observations. All data were analyzed with the SPSS 11.5
statistical  package.  A  one-way  analysis  of  independent
samples  t-test  for  two-sample  comparisons  was  used  to
compare the means of two groups. A p value less than 0.05
was considered statistically significant. The reported results
were representative of three independent experiments.
RESULTS
Changes in endothelial cell morphology during migration and
expression of vascular endothelial cadherin, vimentin, and
Twist:  After  cell  confluency,  EA.hy926  cells  ultimately
formed a cobblestone-like monolayer (Figure 1A). Antibodies
that  recognized  VE-cadherin  yielded  continuous,  linear
staining around the periphery of EA.hy926 cells (Figure 2A),
but there was no expression of Twist protein (Figure 2B) or
vimentin protein (Figure 2C).There was a striking change in
the morphology of the endothelial cells that migrated into the
scratch wound, which developed a fibroblast-like morphology
with visible pseudopods (Figure 1B); VE-cadherin expression
decreased at endothelial cell-cell junctions (Figure 2D); and
antibodies that recognized the cytoskeletal proteins vimentin
(Figure  2E)  and  Twist  (Figure  2F)  were  localized  to  the
cytoplasm. The cells eventually reached confluence again for
durations  of  72  h  and  only  VE-cadherin  protein  was
expressed.
Effect of rapamycin on the growth and migration of EA.hy926
cells: The growth of EA.hy926 cells was not affected by 10
ng/ml or 100 ng/ml rapamycin treatment for up to 72 h. In
contrast, when the EA.hy926 cells were exposed to rapamycin
TABLE 1. PCR PRIMERS OF HUMAN GENE SEQUENCES
Gene name Primer sequence (5′-3′) Gene size
VE-cadherin [40] F: AACTTCCCCTTCTTCACCC 387 bp
  R: AAAGGCTGCTGGAAAATGA  
Vimentin [41] F: GGCTCAGATTCAGGAACAGC 327 bp
  R: GCTTCAACGGCAAAGTTCTC  
Twist [42] F: GGAGTCCGCAGTCTTACGAG 201 bp
  R: TCTGGAGGACCTGGTAGAGG  
GAPDH [17] F: ACCACAGTCCATGCCATCAC 439 bp
  R: TCCACCACCCTGTGGCTGTA  
               Abbreviations: GAPDH represents glyceraldehyde 3-phosphate dehydrogenase, VE represents vascular endothelial.
Figure 1. Cell morphology. A: In the no-scratch group, after cell confluency, EA.hy926 cells formed a cobblestone-like monolayer. B: In the
scratch group, the endothelial cells that migrated into the scratch wound showed a fibroblast-like morphology with visible pseudopods (contrast
phase microscope 100×).
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3408for 72 h, the EA.hy926 cell growth was significantly inhibited
by concentrations of 1000 ng/ml rapamycin (Figure 3).
The effect of rapamycin on the migration of EA.hy926
cells  was  examined  by  using  a  scratch-wound  assay.
Rapamycin  at  concentrations  of  10,100,  and  1000  ng/ml
inhibited  the  migration  of  EA.hy926  cells.  There  were
statistically significant differences between the control group
and the rapamycin groups (10, 100, 1000 ng/ml; Figure 4).
Effect of rapamycin on gene expression cell marker proteins
and  Twist:  After  full  cell  confluency,  there  was  only
expression  of  VE-cadherin  mRNA.  After  scratching,
expression of VE-cadherin in the mRNA level downregulated,
and EA.hy926 cells expressed Twist mRNA and vimentin
mRNA, while 10, 100, and 1,000 ng/ml rapamycin inhibited
the expression of Twist mRNA and vimentin mRNA. There
were  statistically  significant  differences  between  the  no-
scratch group and the scratch group and between the scratch
group and the rapamycin groups (10, 100, and 1000 ng/ml)
(Figure 5, Figure 6).
Effect of rapamycin on matrix metalloproteinase-2 and matrix
metalloproteinase-9  activity:  Results  from  the  gelatin
zymography assay showed that neither MMP-2 nor MMP-9
was detected in the culture supernatants of the no-scratch
group (Figure 7), while there was expression of MMP-2 and
MMP-9 protein in the scratch group and rapamycin groups.
Both  MMP-2  and  MMP-9  were  significantly  reduced  in
EA.hy926 cells with a linear scratch wound with increasing
concentration  of  rapamycin.  There  were  statistically
significant  differences  between  the  scratch  group  and  the
rapamycin  groups  (t=2.954,  5.640,  11.504,  3.056,  3.600,
9.349; p<0.05; Figure 7 and Figure 8).
DISCUSSION
Extracellular microenvironmental changes, such as hypoxia,
result in increased expression of VEGF, which can activate
Figure  2.  Immunofluorescence  images.  A:  In  the  no-scratch  group,  after  cell  confluency,  vascular  endothelial  (VE)-cadherin  yielded
continuous, linear staining around the periphery of EA.hy926 cells (confocal microscopy 200×). B: In the no-scratch group, after cell
confluency, there was no expression of vimentin protein (confocal microscopy 100×). C: In the no-scratch group, after cell confluency, there
was no expression of the Twist protein (confocal microscopy 100×). D: In the scratch group, the VE-cadherin expression of the endothelial
cells that migrated into the scratch wound was decreased at endothelial cell-cell junctions and was mainly localized to the cytoplasm; VE-
cadherin yielded continuous, linear staining around the periphery of EA.hy926 cells on the outside of the scratch wound (confocal microscopy
100×). E: In the scratch group, the vimentin expression of endothelial cells that migrated into the scratch wound (confocal microscopy 100×).
F: In the scratch group, the Twist expression of endothelial cells that migrated into the scratch wound (confocal microscopy 100×).
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3409endothelial  cells.  Activated  endothelial  cells  can  secrete
protease (which dissolves vascular basement membranes) and
extracellular matrix proteins, allowing capillary endothelial
cells to migrate through their basement membrane into the
extracellular matrix to form neovascular buds. This is the
basic pathological process of angiogenesis. Rapamycin can
effectively  inhibit  corneal  neovascularization  and  tumor
angiogenesis [4,7,19]. However, very little is known about
rapamycin’s  mechanism  for  inhibiting  endothelial  cell
migration. This study aimed to fill this knowledge gap by
observing rapamycin’s effects on EndoMT and the production
of MMP-2 and MMP-9.
Numerous studies have shown that tumor cells originated
in epithelial cells that transdifferentiated into mesenchymal
cells,  gained  the  ability  to  migrate,  and  promoted  tumor
metastasis  [20].  When  epithelial  cells  underwent
mesenchymal  transformation,  their  morphology  changed
from a cobblestone-like shape to a spindle-like shape [21,
22].  This  change  in  morphology  was  accompanied  by
decreased  epithelial  markers  (E-cadherin)  and  increased
Twist  and  mesenchymal  markers  (vimentin).  Vimentin,  a
mesenchymal  phenotype  marker,  was  an  intermediate
filament cytoskeletal protein and was widely expressed in
mesenchymal  cells,  which  was  very  closely  related  to
maintaining  the  fibroblasts’  shape  and  permitting  cell
migration. Vimentin was also expressed in HUVEC [23],
which was more especially implicated in cellular motility and
plasticity and was exclusively expressed in the migrating rat
heart endothelial cell line [24].
Figure 3. The effect of rapamycin on EA.hy926 cell growth. EA.hy926 cells were treated with 0 to 1,000 ng/ml rapamycin for 24, 48, or 72
h. Cell growth was determined by methyl thiazolyl tetrazolium assay (MTT). 0 ng/ml of rapamycin represents the control group. Bars represent
standard deviation (SD; n=6 wells per measurement). Similar results were obtained in three independent experiments, and the data were shown
as mean±SD. The asterisk indicates p<0.05, compared with the control group with independent samples t-test.
Figure 4. The effect of rapamycin on the migration of EA.hy926 cells. EA.hy926 cells were treated with 0 to 1,000 ng/ml rapamycin for 8 h.
Cell migration ability was determined by the scratch wound assay method. 0 ng/ml of rapamycin represents the control group. Bars represent
SD (n=6 photographs per measurement). Similar results were obtained in three independent experiments, and the data were shown as mean
±SD. The asterisk indicates p<0.05, compared with the control group with independent samples t-test.
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3410The  transcription  factor  Twist,  a  master  regulator  of
embryonic  morphogenesis,  was  recently  identified  as  an
important promoter of epithelial-to-mesenchymal transition
(EMT) in breast cancers. In this process, Twist directly and
indirectly caused the transcriptional repression of E-cadherin
through  the  E-box  elements  on  the  E-cadherin  promoter,
thereby inducing vimentin expression [20]. Lopez et al. [25]
has  found  that  the  tumor-induced  upregulation  of  Twist
repressed the activity of the human VE-cadherin promoter.
Endothelial  cell  migration  plays  an  important  role  in
angiogenesis  [6].  Endothelial  cells  can  change  into
mesenchymal cells during the embryonic development of the
Figure 5. Reverse transcriptase–PCR gel electrophoresis images of vascular endothelial–cadherin/vimentin/Twist/glyceraldehyde 3-phosphate
dehydrogenase mRNA expression in EA.hy926 cells. The effect of rapamycin on the gene expression of vascular endothelial (VE)-cadherin,
vimentin, and Twist. (a, scratch group; b1, 10 ng/ml rapamycin group; b2, 100 ng/ml rapamycin group; b3, 1,000 ng/ml rapamycin group; c,
no-scratch group).
Figure 6. Relative expression ratio of the target gene versus the housekeeping gene (glyceraldehyde 3-phosphate dehydrogenase). The ratio
for the vertical axis is relative expression ratio of the target gene versus the house-keeping gene (glyceraldehyde 3-phosphate dehydrogenase
[GAPDH]). Three independent experiments were conducted. Bars represent standard deviation (SD), and the data were shown as mean±SD.
The asterisk indicates p<0.05 in comparison between each rapamycin group and the scratch group with independent samples t-test. Pound
sign (#) indicates p<0.05 in comparison between the scratch group and the no-scratch group with independent samples t-test. a, scratch group;
b1, 10 ng/ml rapamycin group; b2, 100 ng/ml rapamycin group; b3, 1,000 ng/ml rapamycin group; c, no-scratch group.
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3411cardiovascular system [26,27]. In that process, endothelial
cells express mesenchymal cell marker proteins and lead to a
marked increase in endothelial migration. We found that VE-
cadherin  was  mainly  distributed  at  endothelial  cell-cell
junctions  after  cell  confluency.  However,  VE-cadherin
expression  decreased  significantly  at  endothelial  cell-cell
junctions and was mainly localized to the cytoplasm after
receiving a scratch wound. At that point, vimentin and Twist
were  expressed  in  migrating  endothelial  cells.  The  cells
eventually reached confluence again for durations of 72 h,
exhibiting a cobblestone-like monolayer and expressing only
the  VE-cadherin  protein.  The  results  of  this  study
demonstrated  that  endothelial  cells  can  transform  into
mesenchymal  cells,  which  can  transition  again  into
endothelial cells, and this process is reversible. We could
conclude  that  Twist,  which  caused  the  transcriptional
repression  of  VE-cadherin  and  induced  the  expression  of
vimentin, might also be an important factor in promoting
EndoMT.
Rapamycin,  isolated  from  a  culture  of  Streptomyces
hygroscopicus,  is  an  immunosuppressant  that  specifically
inhibits  the  mTOR  in  HUVEC  [4].  MTOR  is  a  serine/
threonine protein kinase that plays a crucial role in cell growth,
differentiation,  proliferation,  migration,  and  survival.
Rapamycin can depress EMT induced by transforming growth
factor-β, inhibit rabbit liver fibrosis, and reduce the kidney
and peritoneal damage in the rat remnant kidney model by
inhibiting the mTOR signaling pathway [28-30]. Rapamycin
can inhibit VE-cadherin expression in endothelial cells by
blocking mTOR [31]. This study found that the cell growth of
EA.hy926 cells was significantly inhibited by 1000 ng/ml of
rapamycin with 72 h exposure, but was not affected by short-
term treatment up to 48 h or by concentrations of rapamycin
lower than 1000 ng/ml. It was also observed that rapamycin
at concentrations of 10, 100, and 1000 ng/ml for 8 h exposure
successfully inhibited endothelial cell migration and vimentin
and Twist expression. The results of this study demonstrate
that rapamycin at concentrations of 10 and 100 ng/ml can
effectively  inhibit  endothelial  cell  migration  and  suppress
angiogenesis by depressing Twist expression, which could
inhibit EndoMT without affecting cell growth.
Extracellular matrix degradation (ECM), which allows
capillary endothelial cells to migrate through their basement
membrane into the extravascular organization and provides
Figure 7. Gelatin zymography gel electrophoresis images of matrix metalloproteins 2 and 9 (a, scratch group; b1, 10 ng/ml rapamycin group;
b2, 100 ng/ml rapamycin group; b3, 1,000 ng/ml rapamycin group; c, no-scratch group).
Figure 8. The result of densitometry values of MMP 2 and 9. The effect of rapamycin on the expression of matrix metalloprotein (MMP)-2
and −9 was determined by Gelatin zymography. Three independent experiments were conducted. Bars represent standard deviation (SD), and
the data were shown as mean±SD. The asterisk (*) indicates p<0.05 in comparison between each rapamycin group and the scratch group with
independent samples t-test. a, scratch group; b1, 10 ng/ml rapamycin group; b2, 100 ng/ml rapamycin group; b3, 1000 ng/ml rapamycin group;
c, no-scratch group.
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3412the necessary space for new vessel formation, is an important
process required during angiogenesis. MMPs are a class of
endogenous proteolytic enzymes that are involved in ECM
degradation. In particular, MMP-2 and MMP-9, which can
degrade  ECM  and  activate  many  growth  factors,  play  an
important  role  in  tumor  invasion  and  metastasis  [32,33].
Rapamycin can suppress glioma invasion by blocking the
production of MMP-2 and MMP-9 [13]. Endothelial cells
produce MMPs at lower levels under normal circumstances,
but endothelial cells activated by inflammation, trauma, and
tumor growth can secrete a large number of MMPs that are
activated quickly [34,35]. Some experimental studies have
shown that normal corneal tissues produce MMPs at lower
levels, which can be directly induced by some cytokines such
as VEGF, fibroblast growth factor, and transforming growth
factor and indirectly activated by active urokinase to promote
angiogenesis in a disease state [4,36]. Kwon et al. found that
rapamycin did not change MMP-9 expression in alkaline-
burned  corneal  tissue  [4],  and  this  was  possible  because
angiogenesis  is  a  complex  process  regulated  by  multiple
stimulatory and inhibitory factors in vivo. Some studies have
found that HUVECs could produce MMP-2 and MMP-9 in an
inactive form [37,38]. This experiment found that EA.hy926
cells secreted neither MMP-2 nor MMP-9 when they reached
full confluence, but EA.hy926 cells activated by the scratch
could produce MMP-2 and MMP-9 to increase cell migration.
MMP-2 and MMP-9 were inhibited by 10, 100, and 1000 ng/
ml doses of rapamycin to repress ECM degradation and cell
migration. MMP-2 played an essential role in producing EMT
[39].  Therefore,  rapamycin  might  inhibit  EndoMT  by
depressing MMP-2.
Our data indicate that Twist may also be an important
factor in promoting EndoMT. The possible mechanism for the
inhibition  of  angiogenesis  by  rapamycin  is  as  follows:
Rapamycin inhibited cell migration and extracellular matrix
degradation  by  inhibiting  EndoMT  and  endothelial  cell
secretion  of  MMP-2  and  MMP-9.  These  are  possible
mechanisms for the inhibition of angiogenesis by Rapamycin.
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